Shopping Cart 0
Cart Subtotal
USD 0

Aviragen Therapeutics Inc (AVIR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus; BTA074, a Phase 2 topical antiviral treatment for genital warts; BTA585, an oral fusion protein inhibitor that Aviragen is developing for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a long-acting neuraminidase inhibitor for influenza A and B infections. The Company also has a preclinical RSV non-fusion inhibitor program for its F-protein inhibitor BTA585. Aviragen is headquartered in Alpharetta, Georgia, the US.

Aviragen Therapeutics Inc (AVIR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 12

Merger 13

Aviragen Therapeutics Completes Merger With Vaxart 13

Nabi Biopharma Completes Merger With Biota 14

Licensing Agreements 16

Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 16

Equity Offering 17

Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 17

Biota Pharma Completes Public Offering Of shares For USD 29 Million 18

Asset Transactions 20

Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 20

TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 21

Acquisition 22

Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22

Aviragen Therapeutics Inc-Key Competitors 23

Aviragen Therapeutics Inc-Key Employees 24

Aviragen Therapeutics Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 26

Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 28

May 04, 2017: Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results 29

Feb 02, 2017: Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results 30

Other Significant Developments 32

Apr 04, 2017: Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 12

Aviragen Therapeutics Completes Merger With Vaxart 13

Nabi Biopharma Completes Merger With Biota 14

Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 16

Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 17

Biota Pharma Completes Public Offering Of shares For USD 29 Million 18

Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 20

TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 21

Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22

Aviragen Therapeutics Inc, Key Competitors 23

Aviragen Therapeutics Inc, Key Employees 24

Aviragen Therapeutics Inc, Other Locations 25

Aviragen Therapeutics Inc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aviragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus; BTA074, a Phase 2 topical antiviral treatment for genital warts; BTA585, an oral fusion protein inhibitor that Aviragen is developing for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a long-acting neuraminidase inhibitor for influenza A and B infections. The Company also has a preclinical RSV non-fusion inhibitor program for its F-protein inhibitor BTA585. Aviragen is headquartered in Alpharetta, Georgia, the US.

Aviragen Therapeutics Inc (AVIR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 12

Merger 13

Aviragen Therapeutics Completes Merger With Vaxart 13

Nabi Biopharma Completes Merger With Biota 14

Licensing Agreements 16

Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 16

Equity Offering 17

Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 17

Biota Pharma Completes Public Offering Of shares For USD 29 Million 18

Asset Transactions 20

Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 20

TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 21

Acquisition 22

Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22

Aviragen Therapeutics Inc-Key Competitors 23

Aviragen Therapeutics Inc-Key Employees 24

Aviragen Therapeutics Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 26

Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 28

May 04, 2017: Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results 29

Feb 02, 2017: Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results 30

Other Significant Developments 32

Apr 04, 2017: Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aviragen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Aviragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aviragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

AMRI Enters Into Co-Development Agreement With Biota Holdings For CS8958 12

Aviragen Therapeutics Completes Merger With Vaxart 13

Nabi Biopharma Completes Merger With Biota 14

Aviragen Therapeutics Enters into Licensing Agreement with Georgia State University Research Foundation 16

Biota Pharma Plans to Raise USD25 Million in Public offering of Shares 17

Biota Pharma Completes Public Offering Of shares For USD 29 Million 18

Spero Therapeutics Acquires Antibiotic Assets from Biota Pharma (Aviragen Therapeutics) 20

TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 21

Biota Pharma Acquires Anaconda Pharma for up to USD38 Million 22

Aviragen Therapeutics Inc, Key Competitors 23

Aviragen Therapeutics Inc, Key Employees 24

Aviragen Therapeutics Inc, Other Locations 25

Aviragen Therapeutics Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aviragen Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.